Rethinking Insulin: How Dr. Ibiagbani Max-Harry Is Redefining the Hormonal Architecture of Blood Sugar

By Tosin Clegg

As diabetes cases surge worldwide, research by Dr. Ibiagbani “Ibi” Max-Harry is reframing the science of blood sugar control, expanding the focus beyond insulin to the underlying cellular systems that sustain hormonal balance.

For decades, diabetes research has centred on insulin, including how to replace it, stimulate it, or make the body respond to it. Insulin has been the protagonist of the story. But Dr. Max-Harry, a molecular and cellular biologist trained originally as a biomedical engineer, suspected that another actor had been underestimated: a protein known as parathyroid hormone-related protein, or PTHrP.

“Insulin doesn’t work alone,” she told me during a recent conversation. ‘The pancreas is a system. And systems rarely fail because of one component.”

Her research, completed during her PhD at Ohio University, focused on the nuclear and C-terminal domains of PTHrP, specific regions of the molecule that allow it to function inside cells. What she and her colleagues discovered was striking: when these domains were disrupted in mouse models, pancreatic islet development faltered. Calcium signalling, which is essential for insulin release, became impaired. Insulin secretion declined. Glucagon balance shifted. Glucose control destabilised.

In other words, PTHrP was not merely circulating in the background. It was helping to maintain the internal architecture and communication network of the islet cells themselves.

The pancreas contains clusters of cells known as islets, where insulin-producing beta cells and glucagon-producing alpha cells coordinate blood sugar regulation. A breakdown in this coordination can lead to impaired blood glucose control and eventually the development of diabetes. Dr. Max-Harry’s work suggests that PTHrP plays a foundational role in preserving that coordination, influencing not just hormone release, but cellular development and survival.

Her scientific path began far from Ohio. Growing up in Ghana, she pursued biomedical engineering at All Nations University College, graduating as the institution’s Best Graduating Student in Biomedical Engineering. Engineering, she said, shaped her instincts as a scientist. “Engineering trains you to think in terms of structure and failure analysis. You ask: What holds the system together? What happens when it weakens?”

That systems perspective would define her graduate research. While PTHrP had been studied in bone and other tissues, its nuclear functions in the endocrine pancreas were not well characterised in the pancreas. Much of the literature treated it as an extracellular signalling molecule. Dr. Max-Harry instead probed what the protein was doing inside the nucleus of islet cells, which is a less visible but potentially decisive space.

The implications extend beyond basic biology. In Type 1 diabetes, an autoimmune attack destroys insulin-producing beta cells. In Type 2 diabetes, beta-cell exhaustion occurs due to metabolic stress. In both conditions, preserving beta-cell health remains a central therapeutic goal. By clarifying molecular mechanisms that support islet stability and hormone balance, Dr. Max-Harry’s findings open potential avenues for strategies aimed at protection and regeneration rather than simple hormone replacement.

Her broader research portfolio includes collaborative work examining beta-cell protection and immunomodulatory approaches in Type 1 diabetes — a signal that her interests are not confined to theory but extend toward translational impact.

Today, as an Instructor of Introductory Biology at MIT, she balances research with education. She designs large-enrollment courses serving hundreds of students, experiments with artificial intelligence tools to enhance learning, and mentors aspiring scientists. In her classroom, metabolic pathways become narratives of cause and consequence. “I want students to see molecules as decisions,” she said. ‘They send signals that lead to real-life results”

Her dual identity, engineer and biologist, positions her uniquely within a field often divided between mechanistic detail and systems-level thinking. Diabetes, she argues, is not simply a disease of sugar excess. It is a breakdown in communication, between cells, between hormones, between feedback loops meant to maintain equilibrium.

Globally, more than half a billion people live with diabetes, a number projected to rise sharply in the coming decades. Sub-Saharan Africa is experiencing one of the fastest growth rates, even as research leadership in endocrine biology remains disproportionately concentrated elsewhere. Dr. Max-Harry’s ascent, from Ghanaian engineering student to molecular biologist at one of the world’s leading research institutions, reflects a shifting landscape in global science.

Her work does not promise a cure. Instead, it offers something arguably more durable: clarity. By refining our understanding of how hormone control is structured at the cellular level, she is adding depth to a field long dominated by surface interventions.